Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naive HIV-positive patients

Braitstein, Paula

doi:10.1503/cmaj.045202

Cited by 24 publications

(24 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Increased mortality in co-infected patients has been demonstrated previously [Greub et al, 2000;Monga et al, 2001;Klein et al, 2003;Anderson et al, 2004;Braitstein et al, 2005]. The increased risk of liver disease, decreased use of antiretrovirals, diminished response to HAART and deleterious effects of intravenous drugs have been suggested as possible reasons for the increased mortality in co-infected patients.…”

Section: Discussionmentioning

confidence: 94%

Hepatitis C virus seropositivity in a South African Cohort of HIV co‐infected, ARV naïve patients is associated with renal insufficiency and increased mortality

Parboosing

Paruk

Lalloo

2008

Journal of Medical Virology

View full text Add to dashboard Cite

HIV is known to affect the epidemiology, transmission, pathogenesis and natural history of HCV infection whilst studies on the effects of HCV on HIV have shown conflicting results and are confounded by the influence of intravenous drug use and antiretroviral therapy. This study was conducted in KwaZulu-Natal Province in South Africa where HIV is predominantly a sexually transmitted infection. Intravenous drug use is rare in this region and the study population was naïve to antiretroviral therapy. For this study, specimens from selected sentinel sites submitted to a central laboratory for routine HIV testing were screened for anti-HCV IgG antibodies. HIV positive HCV-positive patients were compared to HIV-positive HCV-negative patients in a subgroup of patients within this cohort in order to determine if HCV sero-prevalence was associated with clinical outcomes in a linked anonymous retrospective chart survey. The prevalence of HCV was 6.4% and that of HIV, 40.2% (n = 1,937). There was a significantly higher prevalence of HCV among HIV infected patients as compared to HIV negative patients (13.4% vs. 1.73% respectively) (n = 1,937, P < 0.001). HCV-HIV co-infected patients had significantly increased mortality (8.3 vs. 21%) (n = 162, P < 0.02). A significant association was found between HCV serostatus and abnormal urea levels (15.4 vs. 7.3 mmol/L, n = 134, P < 0.001) and creatinine levels (252.2 vs. 144.4 micromol/L, n = 134, P < 0.01). This study has found that hepatitis C co-infection is more common in HIV positive individuals and is associated with an increased mortality and renal morbidity.

show abstract

Section: Discussionmentioning

confidence: 94%

Hepatitis C virus seropositivity in a South African Cohort of HIV co‐infected, ARV naïve patients is associated with renal insufficiency and increased mortality

Parboosing

Paruk

Lalloo

2008

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…132,133 In HIV-infected people, HCV seropositivity is an independent predictor of HIV progression and mortality. [134][135][136][137][138] Coinfection increases the rates of perinatal transmission of both viruses.…”

mentioning

confidence: 99%

Hepatitis C: a review for primary care physicians

Wong

Lee²

2006

Canadian Medical Association Journal

View full text Add to dashboard Cite

Primary care physicians see many of the estimated 250 000 Canadians chronically infected with the hepatitis C virus (HCV). Of this number, about one-third are unaware they are infected, which constitutes a large hidden epidemic. They continue to spread HCV unknowingly and cannot benefit from advances in antiviral therapy that may clear them of the virus. Many HCV-infected people remain asymptomatic, which means it is important to assess for risk factors and test patients accordingly. The third-generation enzyme immunoassay for HCV antibodies is a sensitive and specific test, although the presence of the virus can be confirmed by polymerase chain reaction testing for HCV RNA in some circumstances. Pegylated interferon-α and ribavirin combination therapy clears the virus in about 45%-80% of patients, depending on viral genotype. Preventive strategies and counselling recommendations are also reviewed. CMAJ 2006;174(5):649-59 Abstract

show abstract

“…Beberapa studi melaporkan bahwa koinfeksi HIV/HCV dapat mempercepat progresivitas penyakit ke arah sirosis hati 4,5 dan meningkatkan mortalitas yang berhubungan dengan sirosis dekompensata dan karsinoma sel hati. 3,6,7 Lebih lanjut, beberapa studi juga mendapatkan bahwa koinfeksi HIV/HCV dapat meningkatkan risiko transmisi seksual virus hepatitis C. [8][9][10][11][12] Hepatitis C paling mudah ditularkan melalui rute parenteral seperti penggunaan narkotika suntik 13 dan transfusi darah 14 , akan tetapi sulit ditularkan melalui rute seksual. Masih terdapat pro kontra mengenai transmisi seksual virus hepatitis C. Beberapa studi mendapatkan bahwa risiko transmisi seksual hepatitis C memang ada, namun risiko tersebut rendah.…”

Section: Pendahuluanunclassified

Faktor - Faktor yang Berhubungan dengan Kejadian Hepatitis C pada Pasangan Seksual Pasien Koinfeksi Human Immunodeficiency Virus dan Virus Hepatitis C

Kurniawati¹,

Karjadi²,

Gani³

2017

JPDI

View full text Add to dashboard Cite

Pendahuluan. Pencegahan transmisi hepatitis C pada pasangan seksual pasien koinfeksi HIV/HCV merupakan upaya penatalaksanaan hepatitis C. Namun demikian, belum ada data prevalensi hepatitis C dan faktor yang berhubungan dengan transmisi hepatitis C pada pasangan seksual pasien koinfeksi HIV/HCV di Indonesia, sehingga perlu dilakukan penelitian untuk memperoleh data tersebut. Penelitian ini bertujuan untuk mengetahui prevalensi hepatitis C dan faktor-faktor yang berhubungan dengan kejadian hepatitis C pada pasangan seksual pasien koinfeksi HIV/HCV.Metode. Studi potong lintang pada pasangan heteroseksual pasien koinfeksi HIV/HCV yang berobat di Pokdisus RSCM. Faktor yang diteliti meliputi penggunaan narkotika suntik, transfusi darah, status HIV, penggunaan kondom, jumlah hubungan seksual, jumlah pasangan seksual, tipe hubungan seksual dan hitung CD4+ pasien koinfeksi HIV/HCV. Pengambilan data dilakukan dengan wawancara secara terpisah dan pemeriksaan darah antiHCV total dan antiHIV. Analisis statistik dilakukan dengan uji chi-square dan Fisher dan regresi logistik menggunakan program SPSS.Hasil. Selama periode Mei-Agustus 2008, diperoleh 119 subyek penelitian pada rentang usia 19-39 tahun (median 26 tahun) dan 95,8% diantaranya berjenis kelamin perempuan. Didapatkan prevalensi hepatitis C sebesar 10,1%. Hasil analisis bivariat kelompok subyek nonpengguna narkotika suntik didapatkan status HIV reaktif dan hubungan seksual nonvaginal berhubungan dengan kejadian hepatitis C. Pada hasil analisis multivariat didapatkan hanya tipe hubungan nonvaginal yang berhubungan dengan kejadian hepatitis C (adjusted RP 8,051; IK95% 1,215-53,353).Simpulan. Prevalensi hepatitis C pada pasangan seksual pasien koinfeksi HIV/HCV sebesar 10,1%. Tipe hubungan nonvaginal dan status antiHIV positif dapat meningkatkan risiko terjadinya kejadian hepatitis C sebesar 8 kali. Dibutuhkan studi lanjutan dengan sampel yang lebih besar dan desain yang lebih baik untuk menentukan transmisi seksual hepatitis C.

show abstract

Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naive HIV-positive patients

Abstract: we found HCV seropositivity to be an independent predictor of mortality, especially death related to HIV infection.

Cited by 24 publications

References 23 publications

Hepatitis C virus seropositivity in a South African Cohort of HIV co‐infected, ARV naïve patients is associated with renal insufficiency and increased mortality

Hepatitis C virus seropositivity in a South African Cohort of HIV co‐infected, ARV naïve patients is associated with renal insufficiency and increased mortality

Hepatitis C: a review for primary care physicians

Faktor - Faktor yang Berhubungan dengan Kejadian Hepatitis C pada Pasangan Seksual Pasien Koinfeksi Human Immunodeficiency Virus dan Virus Hepatitis C

Contact Info

Product

Resources

About